X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 12 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

10 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

09 11 2023 06:01:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

02 11 2023 08:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

31 10 2023 08:00:13 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

18 10 2023 08:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

19 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

06 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

05 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

10 8 2023 06:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

08 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

03 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

02 8 2023 08:01:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 6 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Expected to Join Russell 3000® Index

13 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 6 2023 16:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

16 5 2023 16:01:00 提供 Nasdaq GlobeNewswire